Identification of citrullinated Hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease

Arthritis and Rheumatism

Volumn 65, Issue 4, 2013, Pages 869-879

  Harlow, Lisa ^a   Rosas, Ivan O ^b   Gochuico, Bernadette R ^c   Mikuls, Ted R ^d   Dellaripa, Paul F ^b   Oddis, Chester V ^e   Ascherman, Dana P ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEAT SHOCK PROTEIN 90 ALPHA ANTIBODY; HEAT SHOCK PROTEIN 90 BETA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN K 562; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; MALE; MASS SPECTROMETRY; MIXED CONNECTIVE TISSUE DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ARTHRITIS, RHEUMATOID; AUTOANTIGENS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CITRULLINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOPRECIPITATION; LUNG DISEASES, INTERSTITIAL; MALE; MASS SPECTROMETRY; MIXED CONNECTIVE TISSUE DISEASE; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SENSITIVITY AND SPECIFICITY;

EID: 84875697859     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37881     Document Type: Article

References (41)

1. Nannini C, Ryu JH, Matteson EL,. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 340-6.
2. Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC,. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003; 48: 917-26.
3. Korkmaz C, Us T, Kasifoglu T, Akgun Y,. Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clin Biochem 2006; 39: 961-5.
4. Turesson C, Jacobsson LT,. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004; 33: 65-72.
5. Young A, Koduri G,. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 907-27.
6. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis: increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007; 46: 350-7.
7. Brown KK,. Rheumatoid lung disease. Proc Am Thorac Soc 2007; 4: 443-8.
8. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010; 62: 1583-91.
9. Afeltra A, Zennaro D, Garzia P, Gigante A, Vadacca M, Ruggiero A, et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scand J Rheumatol 2006; 35: 388-94.
10. Ayhan-Ardic FF, Oken O, Yorgancioglu ZR, Ustun N, Gokharman FD,. Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol 2006; 25: 213-8.
11. Metafratzi ZM, Georgiadis AN, Ioannidou CV, Alamanos Y, Vassiliou MP, Zikou AK, et al. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol 2007; 36: 338-44.
12. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al, and the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
13. Goeldner I, Skare TL, de Messias Reason IT, Nisihara RM, Silva MB, da Rosa Utiyama SR,. Association of anticyclic citrullinated peptide antibodies with extra-articular manifestations, gender, and tabagism in rheumatoid arthritis patients from southern Brazil. Clin Rheumatol 2011; 30: 975-80.
14. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz de Rabago E, Sanchez-Ramon S, Rodriguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61: 419-24.
15. Marasovic-Krstulovic D, Martinovic-Kaliterna D, Fabijanic D, Morovic-Vergles J,. Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis? Rheumatology (Oxford) 2011; 50: 1505-12.
16. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI,. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 2008; 27: 511-3.
17. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K,. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 2008; 41: 1074-7.
18. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, van Venrooij WJ,. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004; 350: 17-34.
19. Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, Turesson C, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 70-5.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
21. Mikuls TR, Kazi S, Cipher D, Hooker R, Kerr GS, Richards JS, et al. The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol 2007; 34: 1480-4.
22. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008; 168: 159-66.
23. Alarcon-Segovia D, Cardiel MH,. Comparison between 3 diagnostic criteria for mixed connective tissue disease: study of 593 patients. J Rheumatol 1989; 16: 328-34.
24. Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009; 60: 2183-92.
25. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
26. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
27. Hayem G, De Bandt M, Palazzo E, Roux S, Combe B, Eliaou JF, et al. Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 291-6.
28. Gizinski AM, Mascolo M, Loucks JL, Kervitsky A, Meehan RT, Brown KK, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol 2009; 28: 611-3.
29. Demoruelle MK, Weisman MH, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, et al. Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum 2012; 64: 1756-61.
30. Egner W,. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000; 53: 424-32.
31. Julkunen H, Ekblom-Kullberg S, Miettinen A,. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol Int 2012; 32: 2445-51.
32. Zong M, Lundberg IE,. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011; 7: 297-306.
33. Labirua A, Lundberg IE,. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010; 22: 633-8.
34. Steen VD,. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35-42.
35. Koenig M, Dieude M, Senecal JL,. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008; 7: 588-93.
36. Taipale M, Jarosz DF, Lindquist S,. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515-28.
37. Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S, et al. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 40-50.
38. Tsan MF, Gao B,. Heat shock proteins and immune system. J Leukoc Biol 2009; 85: 905-10.
39. Sims JD, McCready J, Jay DG,. Extracellular heat shock protein (Hsp)70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One 2011; 6: e18848.
40. Hance MW, Dole K, Gopal U, Bohonowych JE, Jezierska-Drutel A, Neumann CA, et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem 2012; 287: 37732-44.
41. Mikuls TR, Gould KA, Bynote KK, Yu F, Levan TD, Thiele GM, et al. Anticitrullinated protein antibody (ACPA) in rheumatoid arthritis: influence of an interaction between HLA-DRB1 shared epitope and a deletion polymorphism in glutathione S-transferase in a cross-sectional study. Arthritis Res Ther 2010; 12: R213.